Cargando…

Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain

OBJECTIVE: Brain glucose hypometabolism is a prominent feature of Alzheimer's disease (AD), and in this case–control study we used Magnetic Resonance Spectroscopy (MRS) to assess AD‐related differences in the posterior cingulate/precuneal ratio of glucose, lactate, and other metabolites. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Mullins, Roger, Reiter, David, Kapogiannis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846391/
https://www.ncbi.nlm.nih.gov/pubmed/29560372
http://dx.doi.org/10.1002/acn3.530
_version_ 1783305580904972288
author Mullins, Roger
Reiter, David
Kapogiannis, Dimitrios
author_facet Mullins, Roger
Reiter, David
Kapogiannis, Dimitrios
author_sort Mullins, Roger
collection PubMed
description OBJECTIVE: Brain glucose hypometabolism is a prominent feature of Alzheimer's disease (AD), and in this case–control study we used Magnetic Resonance Spectroscopy (MRS) to assess AD‐related differences in the posterior cingulate/precuneal ratio of glucose, lactate, and other metabolites. METHODS: J‐modulated Point‐Resolved Spectroscopy (J‐PRESS) and Prior‐Knowledge Fitting (ProFit) software was used to measure glucose and other metabolites in the posterior cingulate/precuneus of 25 AD, 27 older controls, and 27 younger control participants. Clinical assessments for AD participants included cognitive performance measures, insulin resistance metrics and CSF biomarkers. RESULTS: AD participants showed substantially elevated glucose, lactate, and ascorbate levels compared to older (and younger) controls. In addition, the precuneal glucose elevation discriminated well between AD participants and older controls. Myo‐inositol correlated with CSF p‐Tau(181P), total Tau, and the Clinical Dementia Rating (CDR) sum‐of‐boxes score within the AD group. INTERPRETATION: Higher glucose to creatine ratios in the AD brain likely reflect lower glucose utilization. Our findings reveal pronounced metabolic abnormalities in the AD brain and strongly suggest that brain glucose merits further investigation as a candidate AD biomarker.
format Online
Article
Text
id pubmed-5846391
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-58463912018-03-20 Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain Mullins, Roger Reiter, David Kapogiannis, Dimitrios Ann Clin Transl Neurol Research Articles OBJECTIVE: Brain glucose hypometabolism is a prominent feature of Alzheimer's disease (AD), and in this case–control study we used Magnetic Resonance Spectroscopy (MRS) to assess AD‐related differences in the posterior cingulate/precuneal ratio of glucose, lactate, and other metabolites. METHODS: J‐modulated Point‐Resolved Spectroscopy (J‐PRESS) and Prior‐Knowledge Fitting (ProFit) software was used to measure glucose and other metabolites in the posterior cingulate/precuneus of 25 AD, 27 older controls, and 27 younger control participants. Clinical assessments for AD participants included cognitive performance measures, insulin resistance metrics and CSF biomarkers. RESULTS: AD participants showed substantially elevated glucose, lactate, and ascorbate levels compared to older (and younger) controls. In addition, the precuneal glucose elevation discriminated well between AD participants and older controls. Myo‐inositol correlated with CSF p‐Tau(181P), total Tau, and the Clinical Dementia Rating (CDR) sum‐of‐boxes score within the AD group. INTERPRETATION: Higher glucose to creatine ratios in the AD brain likely reflect lower glucose utilization. Our findings reveal pronounced metabolic abnormalities in the AD brain and strongly suggest that brain glucose merits further investigation as a candidate AD biomarker. John Wiley and Sons Inc. 2018-01-29 /pmc/articles/PMC5846391/ /pubmed/29560372 http://dx.doi.org/10.1002/acn3.530 Text en © Published 2018. This article is a U.S. Government work and is in the public domain in the USA. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Research Articles
Mullins, Roger
Reiter, David
Kapogiannis, Dimitrios
Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
title Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
title_full Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
title_fullStr Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
title_full_unstemmed Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
title_short Magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the Alzheimer's brain
title_sort magnetic resonance spectroscopy reveals abnormalities of glucose metabolism in the alzheimer's brain
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846391/
https://www.ncbi.nlm.nih.gov/pubmed/29560372
http://dx.doi.org/10.1002/acn3.530
work_keys_str_mv AT mullinsroger magneticresonancespectroscopyrevealsabnormalitiesofglucosemetabolisminthealzheimersbrain
AT reiterdavid magneticresonancespectroscopyrevealsabnormalitiesofglucosemetabolisminthealzheimersbrain
AT kapogiannisdimitrios magneticresonancespectroscopyrevealsabnormalitiesofglucosemetabolisminthealzheimersbrain